#1 Clinical Trials Search in Europe

Mogamulizumab

Mogamulizumab is an innovative drug being studied in clinical trials for various types of T-cell lymphomas, including cutaneous T-cell lymphoma (CTCL), mycosis fungoides, and Sézary syndrome. This article explores the ongoing research on mogamulizumab’s effectiveness, safety, and potential combinations with other treatments to improve outcomes for patients with these challenging blood cancers.

Table of Contents

What is Mogamulizumab?

Mogamulizumab, also known by its brand name Poteligeo, is a medication used to treat certain types of blood cancers[1]. It is a type of drug called a monoclonal antibody, which means it’s a laboratory-made protein that targets specific cells in the body[3]. Mogamulizumab is designed to help your immune system fight cancer cells more effectively.

How Does Mogamulizumab Work?

Mogamulizumab works by targeting a specific protein called CCR4 (C-C chemokine receptor 4) that is found on the surface of some cancer cells[9]. By binding to CCR4, mogamulizumab helps your immune system recognize and destroy these cancer cells. This targeted approach allows the medication to focus on cancer cells while minimizing damage to healthy cells.

What Conditions Does Mogamulizumab Treat?

Mogamulizumab is primarily used to treat several types of T-cell lymphomas, which are cancers that affect a type of white blood cell called T-cells. The main conditions treated with mogamulizumab include:

  • Cutaneous T-Cell Lymphoma (CTCL): A group of cancers that primarily affect the skin[1].
  • Mycosis Fungoides (MF): The most common type of CTCL, which causes scaly patches or tumors on the skin[8].
  • Sézary Syndrome (SS): An aggressive type of CTCL that affects both the skin and blood[8].
  • Adult T-cell Leukemia/Lymphoma (ATLL): A rare and aggressive type of T-cell lymphoma[3].

Mogamulizumab is often used when other treatments have not been effective or when the cancer has returned after previous treatment[1].

How is Mogamulizumab Administered?

Mogamulizumab is given as an intravenous (IV) infusion, which means it’s delivered directly into your bloodstream through a vein. The typical dosing schedule is as follows:

  • Initial doses: 1 mg/kg (based on your body weight) given once a week for the first 4-5 weeks[1].
  • Maintenance doses: After the initial doses, the medication is usually given every 2 weeks[1].

Each infusion typically takes at least 60 minutes to complete[1]. Your doctor will determine the exact dosing schedule and duration of treatment based on your individual needs and response to the medication.

Current Clinical Trials

Researchers are continuously studying mogamulizumab to better understand its effectiveness and explore new ways to use it. Some current clinical trials are investigating:

  • Combining mogamulizumab with other treatments, such as phototherapy or other medications, to improve outcomes[10][5].
  • Using mogamulizumab to prevent the development of adult T-cell leukemia/lymphoma in high-risk individuals[3].
  • Evaluating different dosing schedules to find the most effective and convenient regimen for patients[2].

Potential Side Effects

Like all medications, mogamulizumab can cause side effects. Common side effects may include:

  • Infusion reactions (such as fever, chills, or rash during or shortly after the infusion)
  • Skin problems (rash, itching)
  • Diarrhea
  • Fatigue
  • Upper respiratory tract infections

Your healthcare team will monitor you closely for any side effects and can help manage them if they occur[2].

Combination Therapies

Researchers are exploring ways to combine mogamulizumab with other treatments to potentially improve its effectiveness. Some combination therapies being studied include:

  • Mogamulizumab with Total Skin Electron Beam Therapy (TSEB): This combination is being studied for patients with early-stage cutaneous T-cell lymphoma[10].
  • Mogamulizumab with Pembrolizumab: This combination of two immunotherapy drugs is being investigated for advanced-stage, relapsed, or refractory cutaneous T-cell lymphomas[5].
  • Mogamulizumab with DA-EPOCH chemotherapy: This combination is being studied for aggressive T-cell lymphomas[9].

These combination therapies aim to enhance the effectiveness of treatment and potentially provide better outcomes for patients with T-cell lymphomas.

Aspect Details
Drug Name Mogamulizumab (also known as POTELIGEO, KW-0761)
Target Conditions Cutaneous T-cell lymphoma (CTCL), Mycosis fungoides, Sézary syndrome, Adult T-cell leukemia/lymphoma (ATLL)
Mechanism of Action Targets CCR4 receptor on T-cells to inhibit cancer growth and spread
Administration Intravenous infusion, typically 1 mg/kg
Common Dosing Schedule Weekly for first month, then biweekly or monthly in subsequent cycles
Combination Therapies Studied with phototherapy, DA-EPOCH chemotherapy, pembrolizumab, brentuximab vedotin
Primary Outcomes Studied Overall response rate, complete response rate, safety and tolerability
Secondary Outcomes Progression-free survival, overall survival, duration of response, quality of life
Notable Side Effects Infusion reactions, skin rashes, fatigue (severity and frequency being evaluated in trials)

FAQ

  • What is mogamulizumab and how does it work? Mogamulizumab is a humanized monoclonal antibody that targets the CCR4 receptor on certain T-cells. It works by binding to and blocking CCR4, which may help stop the growth and spread of cancerous T-cells in lymphomas.
  • What types of lymphomas is mogamulizumab being studied for? Mogamulizumab is being investigated for various T-cell lymphomas, including cutaneous T-cell lymphoma (CTCL), mycosis fungoides, Sézary syndrome, and adult T-cell leukemia/lymphoma (ATLL).
  • How is mogamulizumab administered in clinical trials? In most trials, mogamulizumab is given as an intravenous (IV) infusion, typically at a dose of 1 mg/kg. The frequency of doses can vary, but often includes weekly doses for the first month, followed by less frequent dosing in subsequent cycles.
  • What are some potential side effects of mogamulizumab? Common side effects may include infusion reactions, skin rashes, and fatigue. More serious side effects can occur but are less common. Clinical trials are closely monitoring patients for any adverse events.
  • Are there any combination therapies being studied with mogamulizumab? Yes, several trials are exploring combinations of mogamulizumab with other treatments. These include combinations with phototherapy, chemotherapy regimens like DA-EPOCH, and other targeted therapies such as pembrolizumab or brentuximab vedotin.

Ongoing Clinical Trials on Mogamulizumab

  • Study of Mogamulizumab and Total Skin Electron Beam Therapy for Patients with Stage IB-IIB Cutaneous T-Cell Lymphoma

    Recruiting

    1 1 1
    Investigated drugs:
    Denmark France Germany Greece Italy Spain

  • Study on the Safety of Mogamulizumab for Patients with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome

    Not recruiting

    1 1 1
    Investigated drugs:
    France Spain

Glossary

  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. Mogamulizumab is a monoclonal antibody designed to target specific T-cells.
  • CCR4: C-C chemokine receptor type 4, a protein found on some T-cells that mogamulizumab targets to help fight cancer.
  • Cutaneous T-cell lymphoma (CTCL): A group of T-cell cancers that primarily affect the skin, including mycosis fungoides and Sézary syndrome.
  • Mycosis fungoides: The most common type of cutaneous T-cell lymphoma, which typically starts as skin patches or plaques.
  • Sézary syndrome: An aggressive type of cutaneous T-cell lymphoma that affects both the skin and blood.
  • Adult T-cell leukemia/lymphoma (ATLL): A rare and aggressive type of T-cell lymphoma associated with HTLV-1 virus infection.
  • Intravenous (IV) infusion: A method of delivering medication directly into a vein using a needle or catheter.
  • Phototherapy: A treatment that uses light to treat skin conditions, sometimes combined with other therapies for skin lymphomas.
  • DA-EPOCH: A chemotherapy regimen that includes dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin.
  • Pembrolizumab: An immunotherapy drug that helps the immune system fight cancer cells.
  • Brentuximab vedotin: A targeted therapy that combines an antibody with a chemotherapy drug to treat certain lymphomas.

References

  1. https://clinicaltrials.gov/study/NCT06285370
  2. https://clinicaltrials.gov/study/NCT04745234
  3. https://clinicaltrials.gov/study/NCT06698003
  4. https://clinicaltrials.gov/study/NCT02867007
  5. https://clinicaltrials.gov/study/NCT05956041
  6. https://clinicaltrials.gov/study/NCT06235281
  7. https://clinicaltrials.gov/study/NCT05414500
  8. https://clinicaltrials.gov/study/NCT04256018
  9. https://clinicaltrials.gov/study/NCT05996185
  10. https://clinicaltrials.eu/trial/study-of-mogamulizumab-and-total-skin-electron-beam-therapy-for-patients-with-stage-ib-iib-cutaneous-t-cell-lymphoma/